Efficacy of lipid-lowering and anti-inflammatory effects of statins sequential therapy in coronary ;heart disease patients undergoing elective PCI / 中国介入心脏病学杂志

ABSTRACT

Objective To assess the inlfuence and safety of early atorvastatin sequential therapy in coronary heart disease (CHD) patients underdoing elective percutaneous coronary intervention on selected indicators of inflammation and serum lipids. Methods A total of 88 CHD patients who got ready to receive the elective percutaneous coronary intervention (PCI) were divided in two groups at randomThe sequential dose group was called group A (atorvatatin 80mg as loading dose ,40 mg/d for 1 month after PCI and 20 mg/d subsequently, n=43), and the ordinary dose group was called group B ( atorvastatin 20 mg/d, n=45). During the follow-up, blood samples were taken at baseline, 3 days,1 month, 3 months and 6 months for myeloperoxidase (MPO), matrix metalloproteinase-9(MMP-9), serum lipids, serum alanine aminotransferase (ALT), glutamyl endopeptidase (GGT) and creatine kinase (CK) levels. Main adverse cardiac events and adverse effects were also analyzed. Results Compared with the baseline, the level of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) was signiifcantly decreased in both two groups after treatment (P 0.05). Reduction in MMP-9 also showed signiifcant in both groups after treatment (group AF=46.911, P=0.00;group BF=19.156, P=0.00). The adverse effects had no signiifcant differences between the 2 groups (P>0.05). Conclusions The atorvastatin sequential theapy in CHD patients undergoing elective percutaneous coronary intervention could decrease serum lipids signiifcantly. Pretreatment with atorvastatin for patients undergoing PCI could inhibit inlfammation. The MACE and adverse effects were similar between the two groups.